---
title: 'Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-na√Øve Crohn''s
  Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study'
date: '2023-07-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37523666/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230801180916&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The results of this prospective, 2-year, real-world evidence
  study suggest that the choice of VEDO led to higher remission rates after 2 years
  compared with anti-TNF. This could support the role of VEDO as a first-line biologic
  therapy in ...'
disable_comments: true
---
CONCLUSIONS: The results of this prospective, 2-year, real-world evidence study suggest that the choice of VEDO led to higher remission rates after 2 years compared with anti-TNF. This could support the role of VEDO as a first-line biologic therapy in ...